Cipla said that it has entered into an exclusive license and supply agreement with Chia Tai Tianqing Pharmaceutical Group Co. for Rolditamig Deuderuxtecan, a potential best-in-class HER2 bispecific antibody-drug conjugate (ADC).
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.